We are live on ! Find out more
ZVSA

ZyVersa Therapeutics
ZVSA

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

1 hedge funds and large institutions have $1 invested in ZyVersa Therapeutics in 2025 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

1.38% less ownership

Funds ownership: 1.38% → 0% (-1.4%)

83% less funds holding

Funds holding: 6 → 1 (-5)

83% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 6

100% less capital invested

Capital invested by funds: $44.7K → $1 (-$44.7K)

Holders
1
Holders Change
-5
Holders Change %
-83.33%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GA
Guerra Advisors
Florida
+$4

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$26.6K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$14.7K
3
TRCT
Tower Research Capital (TRC)
New York
-$3.06K
4
Citigroup
Citigroup
New York
-$186
5
SS
SBI Securities
Japan
-$102

ZVSA Hedge Fund Activity: Q3 2025 in Review

1 of the 7,638 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q3 2025, worth a combined $1 — down 100% from $44.7K a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of ZVSA and 1 opened new positions — a net loss of 5 holders — while 0 trimmed existing stakes and 0 added.

The largest buyer was Guerra Advisors, opening a new position worth an estimated $4. The largest seller was UBS Group, exiting entirely with an estimated $26.6K sold.

  • 1 institutional investor held ZyVersa Therapeutics (ZVSA) as of Q3 2025, down from 6 in Q2 2025.
  • Funds reported $1 of ZyVersa Therapeutics stock for Q3 2025, down 100% quarter-over-quarter.
  • 1 fund opened new ZyVersa Therapeutics positions in Q3 2025 and 6 closed out, a net change of -5 holders.
  • The largest ZyVersa Therapeutics buyer in Q3 2025 was Guerra Advisors, an estimated $4 added.
  • The largest ZyVersa Therapeutics seller in Q3 2025 was UBS Group, an estimated $26.6K sold.

Based on aggregated 13F filings for Q3 2025.